Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07OZR
|
||||
Former ID |
DCL000248
|
||||
Drug Name |
TKI258
|
||||
Synonyms |
Chir 258; CHIR-258; TKI-258; TKI-258, Dovitinib, CHIR258, TKI258; 4-Amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Anticancer Agents
|
||||
Company |
Novartis & Chiron Corp
|
||||
Structure |
Download2D MOL |
||||
Formula |
C21H21FN6O
|
||||
InChI |
InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11,24-25H,7-10,23H2,1H3/b20-18-
|
||||
InChIKey |
KCOYQXZDFIIGCY-ZZEZOPTASA-N
|
||||
CAS Number |
CAS 804551-71-1
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
14854259, 16526641, 16823163, 39896483, 45633748, 50100092, 56374260, 74418884, 109693511, 121280185, 135261170, 136367994, 141243978, 141243980, 141913081, 141913174, 144115820, 152258853, 152344214, 160647703, 162205181, 164044350, 174529303, 177748727, 178102585, 180190845, 188899516, 196378498, 198975799, 223397268, 226534136, 235322191, 249565565, 249565566, 249565567, 249582865, 251856461, 252215131, 252543299
|
||||
Target and Pathway | |||||
Target(s) | FGF-3 receptor | Target Info | Inhibitor | [536474] | |
Platelet-derived growth factor receptor | Target Info | Inhibitor | [536474] | ||
PANTHER Pathway | FGF signaling pathway | ||||
Reactome | FGFR3 mutant receptor activation | ||||
References | |||||
Ref 536674 | A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2008 Apr 1;14(7):2075-81. | ||||
Ref 541242 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5962). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.